About the report
The analysis is split into:
-
- The Drug Landscape: An analysis of all 2000+ assets in the ADC database by drug phase, target, disease indication, and more.
- The Trial Landscape: An analysis of the 2900+ clinical trials tracked on Beacon ADC and a deeper look into trends within the space, including disease indications and investments.
- The Commercial Market: A review of $150bn worth of ADC deals from 2023, highlighting popular deal structures and insights into Asia’s success in the market.
- The Future of ADCs: A glimpse into the future trajectory of the ADC space from a preclinical drug development perspective.
- Regulatory Announcements: A review of every regulatory announcement from 2023.
You may also be interested in...
Exploring the Synergy of ADCs in Combination with Checkpoints – A Comprehensive Review
The 2023 ADC Landscape Review
The Rise of ADCs and Novel Drug Conjugates in Asia
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
Speak with our team
Our dedicated ADC account and research teams can help you with questions by showing you how this insight and data is collated on Beacon.
